Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tolterodine
Drug ID BADD_D02244
Description Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
Indications and Usage For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Marketing Status approved; investigational
ATC Code G04BD07
DrugBank ID DB01036
KEGG ID D00646
MeSH ID D000068737
PubChem ID 443879
TTD Drug ID D0BZ7W
NDC Product Code 13668-189; 13668-190; 0904-6592; 60687-330; 0904-6593; 65427-022; 60687-319
UNII WHE7A56U7K
Synonyms Tolterodine Tartrate | Tartrate, Tolterodine | Tolterodine | Detrol | Detrol LA | Urotrol | PHA-686464B | PHA 686464B | PHA686464B | Detrusitol | Unidet
Chemical Information
Molecular Formula C22H31NO
CAS Registry Number 124937-51-5
SMILES CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urinary incontinence17.05.01.008; 20.02.02.0100.001266%
Urinary retention20.02.02.0110.000792%
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.0010.000995%
Vertigo04.04.01.003; 17.02.12.0020.000226%
Vision blurred06.02.06.007; 17.17.01.0100.001493%
Visual acuity reduced06.02.10.012; 17.17.01.0110.000882%
Visual impairment06.02.10.0130.002261%-
Weight increased13.15.01.006--
Xerophthalmia06.06.03.008; 14.12.03.002---
Hypoacusis04.02.01.0060.001379%
Peripheral swelling02.05.04.015; 08.01.03.053---
Balance disorder08.01.03.081; 17.02.02.0070.000226%-
Bladder disorder20.03.01.0020.000769%-
Drug intolerance08.06.01.0130.001922%-
Renal impairment20.01.03.0100.000226%-
Treatment failure08.06.01.0170.001153%-
Frustration tolerance decreased19.04.02.0160.000498%-
Penile erythema21.12.01.017---
Illness08.01.03.0910.000882%-
Therapeutic product effect decreased08.06.01.050---
Therapeutic product effect delayed08.06.01.0510.000769%-
Therapeutic product effect incomplete08.06.01.0520.005111%-
The 4th Page    First    Pre   4    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene